Peptides by Condition

Peptides explored for joint pain and arthritis — BPC-157, TB-500, GHK-Cu, and KPV — with mechanism, what the evidence actually shows, and how they sit alongside conventional care.

Peptides for type 2 diabetes — semaglutide, tirzepatide, exenatide, liraglutide, mazdutide — with mechanism, evidence from pivotal RCTs and outcomes trials, and the role peptide therapy now plays alongside metformin and lifestyle care.

Peptides for tendonitis and tendon healing — BPC-157 and TB-500 dominate the conversation. Mechanism, animal evidence, and what realistic recovery looks like.

Peptides studied for brain fog and cognitive sluggishness — Semax, Selank, Cerebrolysin, Dihexa, GSB-106, and PE-22-28. What the Russian-Soviet nootropic literature actually shows.

Peptides marketed for hair loss — GHK-Cu, AHK-Cu, and Pal-AHK. Mechanism, evidence quality, and how they compare to minoxidil and finasteride.

Peptides for wrinkles and skin aging — GHK-Cu, Argireline, SNAP-8, Matrixyl, and the cosmetic peptide family. What actually works topically.

Peptides relevant to low testosterone — kisspeptin, gonadorelin, hCG, hMG, enclomiphene — with mechanism, evidence, the role of HPG-axis stimulation versus testosterone replacement, and how peptide therapy fits clinical practice.

Peptides explored for knee pain — BPC-157, TB-500, GHK-Cu, pentosan polysulfate — with mechanism, evidence in cartilage and soft-tissue repair, and how peptide therapy fits alongside physical therapy and conventional care.

Peptides explored for back pain — BPC-157, KPV, TB-500 — with honest framing about which back pain types respond, what the evidence shows, and why structural and neurological causes still need conventional evaluation.

Peptides for wound healing — GHK-Cu (the best-evidenced), BPC-157, TB-500, LL-37, and AC-SDKP. What the wound-care literature actually shows.

Peptides explored for leaky gut and intestinal permeability — BPC-157, KPV, larazotide, and GLP-2 / teduglutide. What the science actually says.

Peptides discussed for anxiety — Selank, Semax, oxytocin, and neuropeptide-S. Mechanism, clinical history, and how they compare to standard anxiolytics.

Peptides discussed for erectile dysfunction — PT-141 / bremelanotide (FDA-approved for HSDD), kisspeptin, and Vesilute. Mechanism, evidence, and how they relate to PDE5 inhibitors.

Peptides explored for plantar fasciitis — BPC-157, TB-500, GHK-Cu — with mechanism rationale, what's actually known about connective-tissue healing, and how peptide therapy fits alongside conventional first-line care.

Peptides explored for NAFLD and MASLD — semaglutide, tirzepatide, survodutide, retatrutide, MOTS-c — with mechanism, evidence from biopsy-controlled trials, and how peptide therapy fits the rapidly evolving fatty liver treatment landscape.

Peptides explored for depression — Selank, Semax, Cerebrolysin — with honest framing about why SSRIs and SNRIs remain first-line, where peptide therapy might add value, and the strict caveats around treating mood disorders.

Peptides explored for ADHD — Semax, Selank — with honest framing about Russian clinical use, why stimulants remain first-line, and where peptide therapy might add value as an adjunct.

Peptides explored for post-COVID brain fog and long COVID cognitive symptoms — Cerebrolysin, Semax, Selank, BPC-157 — with honest framing about emerging evidence, mechanism, and how peptide therapy fits the long COVID treatment landscape.

Peptides explored for insomnia — DSIP, epithalon, selank — with mechanism rationale, evidence in sleep architecture and circadian regulation, and how peptide therapy fits alongside CBT-I and conventional sleep medicine.

Peptides explored for long COVID (PASC) — BPC-157, Cerebrolysin, thymosin alpha-1, KPV — with honest framing about the heterogeneous syndrome, mechanism alignment with neuroinflammation and vascular dysfunction, and where peptide therapy fits alongside multimodal rehabilitation.

Peptides explored for PCOS — semaglutide, tirzepatide, exenatide, liraglutide — with mechanism, evidence in metabolic and reproductive outcomes, and how peptide therapy fits alongside lifestyle care, metformin, and inositol.

Peptides explored for acne — KPV topically, with copper peptides and antimicrobial peptides — with honest framing about why retinoids and conventional therapy remain primary, and where peptides may add anti-inflammatory support.

Peptides for low libido in women — PT-141 (Vyleesi, FDA-approved for HSDD), oxytocin — with mechanism, evidence from pivotal trials, and how peptide therapy fits the female sexual wellness landscape.

Peptides discussed for autoimmune disease — thymosin alpha-1, KPV, BPC-157 — with strict caveats: peptides are at-most adjuncts, never replacements for evidence-validated DMARDs, biologics, and immunosuppressive therapy.

Peptides discussed for chronic pain — BPC-157 most prominent — with honest framing about why chronic pain is heterogeneous, what peptides can and cannot do, and how peptide therapy fits multimodal pain management.

Peptides discussed for irritable bowel syndrome — BPC-157, KPV, and the FDA-approved peptide linaclotide for IBS-C. Mechanism, evidence, and realistic expectations.

Peptides discussed for chronic inflammation — BPC-157, KPV, thymosin-α1, LL-37, VIP, and PEPITEM. Mechanisms, evidence, and the inflammaging context.

Peptides discussed for chronic fatigue and mitochondrial dysfunction — MOTS-c, SS-31 / elamipretide, humanin, thymosin-α1, and BPC-157. Mechanism and evidence.

Peptides explored for sarcopenia — MOTS-c, follistatin, CJC-1295, ipamorelin, tesamorelin — with mechanism rationale, evidence in age-related muscle loss, and how peptide therapy fits alongside resistance training and protein optimization.

Peptides explored for frozen shoulder (adhesive capsulitis) — BPC-157, TB-500, GHK-Cu — with mechanism rationale, evidence in soft-tissue contracture, and how peptide therapy fits alongside physical therapy and capsular release.

Peptides discussed for sciatica — BPC-157 most prominent — with honest framing about why peptide therapy is fundamentally limited for nerve compression, when surgery or epidural injection matters, and where peptides might help.

Peptides discussed for fibromyalgia — BPC-157, Selank, KPV — with honest framing about central pain biology, what peptides can and cannot do, and how they fit alongside evidence-validated care including LDN, antidepressants, and pacing.

Peptides discussed for SIBO — BPC-157, KPV, larazotide — with honest framing about why rifaximin remains primary therapy and where peptides may help with mucosal recovery and gut motility support.

Peptides discussed for GERD — BPC-157 most prominent — with honest framing about why PPI therapy remains primary, the limits of peptide effects, and where mucosal repair support might help.

Peptides discussed for ulcerative colitis — BPC-157, KPV, larazotide — with strict caveats: peptides are at-most adjuncts, never replacements for evidence-based IBD therapy. Disease-modifying therapy comes from gastroenterology specialists.

Peptides discussed for Crohn's disease — BPC-157, KPV, larazotide, thymosin alpha-1 — with strict caveats: peptides are at most adjuncts, never replacements for evidence-validated biologic and immunomodulator therapy.

Peptides explored for melasma — decapeptide-12, oligopeptide-68 — with mechanism rationale targeting tyrosinase and melanin pathways, evidence in pigmentation reduction, and how peptide therapy fits alongside conventional treatment.

Peptides explored for eczema — KPV, LL-37 considerations, copper peptides — with honest framing about why dupilumab and conventional therapy remain primary, and where peptides may add anti-inflammatory or barrier-supportive value.

Peptides explored for stretch marks — GHK-Cu, Matrixyl, copper peptides — with mechanism rationale for collagen and elastin remodeling, evidence in striae treatment, and how peptide therapy fits alongside retinoids and procedural care.

Peptides explored for scarring — GHK-Cu, AC-SDKP, copper peptides — with mechanism rationale for matrix remodeling and anti-fibrotic effects, evidence in different scar types, and how peptide therapy fits alongside conventional scar management.

Peptides explored for recurrent infections — thymosin alpha-1, LL-37, antimicrobial peptides — with mechanism rationale, evidence in immune modulation, and how peptide therapy fits alongside conventional immunology workup and care.

Peptides discussed for neuropathic pain — BPC-157, Cerebrolysin — with honest framing about limited evidence, why gabapentinoids and SNRIs remain primary, and where peptides may have a narrow adjunct role.

Peptides explored for migraines — with the important caveat that CGRP-pathway drugs (the most relevant modern migraine therapy) are antibodies, not peptides. Honest framing about the actual peptide landscape and where conventional CGRP therapy sits.

Peptides discussed for vaginal atrophy and GSM — GHK-Cu and tissue-supportive peptides — with honest framing about why local estrogen therapy remains primary, and where peptide therapy may add modest tissue support.

Peptides discussed in hypertension — ANP, BNP — with honest framing about why they are biomarkers rather than therapy, what conventional antihypertensive medications remain, and where peptide-related research is heading.

Peptides explored for heart failure and rare cardiomyopathies — elamipretide (FDA-approved 2025 for Barth syndrome), MOTS-c — with honest framing about narrow validated indications and where peptides fit alongside conventional heart failure therapy.